Physician profile
Michael A Lerner
NPI 1508849308
$5,748.69
in general payments reported to CMS, 2019-2025
37 companies · $987 in 2025
The $987 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $418 · 2021: $868 · 2022: $1,009 · 2023: $854 · 2024: $1,259 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,099.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,118.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $816.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $551.44 | 2021-2025 | |
| Glaxosmithkline, LLC. | $414.94 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Supernus Pharmaceuticals, INC. | $342.92 | 2019-2022 | |
| Lilly USA, LLC | $289.33 | 2019-2025 | Jardiance, Zepbound, Emgality |
| Pfizer INC. | $237.75 | 2019-2024 | |
| Astellas Pharma US INC | $230.37 | 2021-2025 | Veozah |
| Edwards Lifesciences Corporation | $174.08 | 2022 | |
| Merck Sharp & Dohme LLC | $144.02 | 2019-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Sage Therapeutics, LLC | $140.36 | 2024-2025 | Zurzuvae |
| Abbott Laboratories | $133.04 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $122.88 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.60 | 2021-2025 | Jardiance |
| Amgen INC. | $102.12 | 2019-2024 | Prolia, Evenity, Otezla |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.